

PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY

59 ONE MILE ROAD EXTENSION
EAST WINDSOR, NJ 08520
(609) 443-4500 / FAX: (609) 443-4030
WINDSORDERMATOLOGY@WINDSORDERMATOLOGY.COM

PSORIASIS TREATMENT CENTER

1985 – Present Psoriasis Treatment Center of Central New Jersey.
Facilities include Broad band UVB, PUVA, narrow band UVB, hand/foot phototherapy, biological therapy, and clinical trials.

CLINICAL TRIALS

- 2015 Corrona Registry
- 2015 A Phase III, Multi-Center, Double-Blind, Randomized, Vehicle Controlled Clinical Study To Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.
- 2015 A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.
- 2015 A Multi-Center, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.
- 2015 An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
- 2015 A Prospective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor. Sponsored by Actelion Pharmaceuticals US, Inc.
- 2015 A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis. Sponsored by Celgene Corporation.
- 2015 An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who participated in Previous Dupilimab Clinical Trials. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2015 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose

Regimens Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

- 2015 Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Jerry Bagel, MD
- 2015 Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis. Sponsored by Qurient
- 2014 A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilimab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2014 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pego in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UBC Biopharma, SPRL
- 2014 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen Research & Development, LLC
- 2014 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis. Sponsored by Novartis Pharmaceuticals Corporation
- 2014 Characterization of Chronic Inflammatory Skin Disease. Sponsored by TRBIO
- 2014 A Small Methods Study Involving Electronic Data Collection in Normal Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic. Sponsored by HRA
- 2014 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma

- 2014 A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Valeant
- 2014 A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis. Sponsored by AbbVie
- 2014 A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with Moderate to severe plaque psoriasis. Sponsored by Novartis
- 2014 A 48 weeks study of three different dose regimens of BI 655066 Administered subcutaneously in patients with moderate to severe Chronic plaque psoriasis (randomized, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066). Sponsored by Boehringer Ingelheim
- 2013 A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% Versus Vehicle Lotion in Subjects with Plaque Psoriasis. Sponsored by Therapeutics Inc.
- 2013 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis with Taclonex® Topical Suspension and Effect on Quality of Life. Investigator Sponsored.
- 2013 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis. Sponsored by Promius
- 2013 A Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of the Investigational Drug in Plaque Psoriasis Patients. Sponsored by Maruho
- 2013 Eli Lilly: A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period
- 2013 Eli Lilly: Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector Patients with Moderate-to-Severe Plaque Psoriasis
- 2012 Janssen Biotech: A Phase 3b, Randomized, Double-Blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored”

Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis

- 2012 Eli Lilly: Phase 2b A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients with Moderate-to-Severe Plaque Psoriasis
- 2011 Amgen: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE-3
- 2011 Amgen: Open Label Study to evaluate the efficacy and safety of Entanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
- 2011 Galderma: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Parallel Group Study to Demonstrate The Efficacy and Assess The Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated With Rosacea.
- 2011 Anterior Hyperhidrosis: To Evaluate Sweat Production in Subjects With Primary Axillary Hyperhidrosis in Adults.
- 2011 Prometheus: Collection of Blood Samples for Developing Assays to measure Drug Levels and Anti-Drug Antibody Levels in Subjects treated with Humira
- 2011 No compounds 04001: A Multicenter, Observational, Non interventional, Narrative Study to Evaluate Patient-reported Experiences of Living with Moderate to Severe Plaque Psoriasis
- 2010 Celgene: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (Cc-10004) In Subjects with Mild to Severe Plaque Psoriasis
- 2010 Vitiligo: A Single Center, Single-Arm, Open-Label, Pilot Trial to Evaluate The Safety, Effectiveness, and Impact on Quality of Life. Adalimumab Treatment in Adults with Stable Generalized Vitiligo Vulgaris
- 2010 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Entercept in Subjects with Moderate to Severe Plaque Psoriasis
- 2009 – Present Effectiveness and Safety of 3 Dosing Regimens of CP – 690, 550 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis sponsored by Pfizer
- 2009 – Present Moderate to Severe Plaque Psoriasis with Scalp Involvement_sponsored by Amgen

2009 – Present	Trial to Evaluate the Effectiveness and Safety of HUMIRA in Combination with Narrowband UVB (NB-UVB) Phototherapy for the Treatment of Psoriasis sponsored by Abbott
2009	A Controlled Study of Humira in Subjects with Chronic Plaque Psoriasis of Hands and/or Feet
2009	Esprit Registry
2008	Psolar Registry
2007	Observe Registry
2008	Abbott Protocol M06-890: Phase III: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled study comparing the Safety and Efficacy to Two Regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis
2008	Genentech Protocol ACD4412n: A Phase IV Randomized Double-Blind Placebo Controlled Study to Evaluate The Safety and Efficacy of 1.0 Mg/Kg EFALIZUMAB In Adult Patients with Moderate to Severe Plaque Psoriasis with The Involvement of The Scalp.
2008	Atlanta Protocol 0416-01-01: A multi-Center Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Altana Inc's Tacrolimus ointment 0.1% to Protopic (Tacrolimus) Ointment 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis.
2007	A Single-Center, Prospective, Single-Blind, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients with Psoriasis on Light Therapy.
2007	A Clinical Evaluation of Safety and Efficacy of Adding Topical Coal Tar Solution to Standard UVB Phototherapy Administered 3 Times Weekly to Patients with Generalized Psoriasis: a Pilot Study.
2007	A Comparative Pharmokinetic Evaluation of 4% Trade Name (Fluorouracil) Cream Vs Efudex Cream in Patients with Actinic Keratosis: Hill Dermaceuticals Inc.
2005-06	A Phase 3 Multi-centered, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis: Centocor, Inc.
2005-06	A Phase III, Long-term, Open Label Study to Evaluate the Safety of Twice-daily Tacrolimus Cream-B in the Treatment of Psoriasis: Astellas, Inc.

2005 A Multicenter, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of Enbrel in Combination with narrowband UVB Phototherapy for the Treatment of Psoriasis: Amgen, Inc.

2005 Safety and Efficacy Evaluation of Tretinoin Gel, 0.05% versus Tretinoin Gel Vehicle in the Treatment of Mild to Moderate Acne Vulgaris: Healthpoint, Ltd.

2005 Point in Time Collection Protocol in Order to Build a Repository of DNA Specimens from Donor/Participants with Genetic and Clinical Signs of Psoriasis with a matched Control Group: BioCollections, Inc.

2004 Atlas Registry

2004 Phase IV Psoriasis Study to Evaluate Safety and Efficacy of an Extended Course of Alefacept, following a Standard 12-Week Course of Amevive: Biogen, Idec.

2004 Phase II Psoriasis Study Evaluations STA S326: Synta Pharmaceuticals

2004 Phase II Psoriasis Study Evaluating Psoraxine/AS210: Astralis, Inc.

2004 Phase 3b Psoriasis Study Evaluating Etanercept: Amgen, Inc.

2004 Phase II Psoriasis Study Evaluating CNTO 1275: Centocor, Inc.

2004 Phase III Psoriasis Study Evaluating 0.3% FK506 Gel vs. Gel Vehicle: Fujisawa Healthcare, Inc.

2003 Phase 1 Psoriasis Study Evaluating IM AS210 in Moderate Psoriasis: Astralis, Ltd.

2004 SQ IL-12 Monoclonal Antibody In Psoriasis: Centocor

2003 Alefacept in Psoriatics Weighing Between 100kg –150kg: Biogen

2003 SQ Enbrel 50mg BIW in Moderate to Severe Psoriasis.

2003 CD4 Antibody Study in Patients with Moderate to Severe Psoriasis: Genmab

2003 Tuporal Capsules in Patients with Moderate to Severe Psoriasis: Stifle Laboratory

2002 A Phase 2, Randomized, Double-Blind Study of 0.1% and 0.5% Tacrolimus Cream Versus Cream Vehicle in the Treatment of Mild to Moderate Plaque Psoriasis in Adults: Fujisawa

2002 SQ ENBREL in Moderate to Severe Psoriasis: Amgen

2002 B-Clear in Localized Psoriasis: Lumenis

2002 Calcitrol 3ug/g Ointment in Psoriasis; Galderma

2001 A Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Clinical Trial of ABX-IL8 in Patient with Moderate to Severe Plaque Psoriasis: Abgenix

2001 A Phase 2, Randomized, Double-Blind Study of 0.3% Tacrolimus Gel versus Gel Vehicle in the Treatment of Mild to Moderate Psoriasis in Adult Subjects: Fujisawa

2001 A Randomized, Double-Blind, Parallel Group Evaluation of Clobetasol Propionate Shampoo, 0.05% versus Its Vehicle – An Efficacy and Safety Study in Subject with Scalp Psoriasis: Galderma

2000 Phase II Psoriasis Study; Evaluating PVAC: Corixa

2000 Phase II Psoriasis Study; Evaluation topical FK8453 Gel: Fujisawa

2001 Phase III Psoriasis Study; evaluating subcutaneous anti-CD11a: Genentech

2000 Phase III Psoriasis Study; evaluating subcutaneous anti-CD11a: Genentech

1999 Evaluate safety of Topical Tacrolimus Ointment for the Treatment of Atopic Dermatitis: Fujisawa

1999 Evaluate Safety and Efficacy of Tazarolene Cream 0.1% in Acne: Allergan

1999 A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle – Controlled Study of The Efficacy and Safety of Fluticasone Propionate Lotion 0.05% Applied Once Daily for Four Weeks in the Treatment of Adult and Pediatric Subjects with Moderate to Severe Atopic Dermatitis (with GlaxoWellcome).

1998-2002 Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study of BG9273 in subjects with Moderate to Severe Plaque Psoriasis (with Biogen).

1998 Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Study of the Safety and Efficacy of 0.05% and 0.1% Tazarotene Creams applied once daily for 12 weeks in the Treatment of Plaque Psoriasis (with Allergan).

1997 A Double-Blind, Randomized, Parallel Study Comparing Two Formulations of 12% Ammonium Lactate Lotion and a Placebo for the Treatment of Ichthyosis Vulgaris (with Clay Park Labs).

1998 L-733, 725 Multiple Oral Dose Safety, Tolerability, and Biological Activity Study in Psoriatic Patients (with Merck Pharmaceutical).

1996 L-733, 725 Multiple Oral Dose Safety, Tolerability, and Biological Activity Study in Psoriatic Patients (with Merck Pharmaceutical).

1997 L-733, 725 Multiple Oral Dose Safety, Tolerability, and Biological Activity Study in Psoriatic Patients (with Merck Pharmaceutical).

1995 & 1997 Phase II of a Double Blind, Placebo-Controlled, Randomized, Trial of DAB389IL-2 in Patients with Moderate to Severe Plaque Psoriasis (with Seragen Pharmaceutical).

1993 – 1994 A Double Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Effects of Cyclosporine a on an Ex-Vivo Stimulation Assay and on a Calcineurin Phosphatase Assay In Patients with Chronic Plaque Psoriasis (With Merck Pharmaceutical).

HOSPITAL AFFILIATIONS

University Medical Center at Princeton NJ

FOREIGN LANGUAGES SPOKEN

Spanish, Italian, Yiddish, French.